1 |
Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of -FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-9
|
2 |
Yun M, Lim J, Noh S, Hyung WJ, Cheong JH, Bong JK, et al. Lymph Node Staging of Gastric Cancer Using FDG PET; A Comparison Study with CT. J Nucl Med 2005;46:1582-8
|
3 |
Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95
DOI
ScienceOn
|
4 |
Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25
DOI
|
5 |
Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using -FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-55
DOI
|
6 |
Ko D, Yun M, Lim J, Noh S, Ryu Y, Lee JD. Detection of peritoneal carcinomatosis in patients with gastric adenocarcinoma: Is PET more accurate than CT. J Nucl Med (Abstract) 2005;425P
|
7 |
Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-21
DOI
ScienceOn
|
8 |
Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of -2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-53
DOI
|
9 |
Lee HJ, Yun M, Ko D, Ryu YH, Lee JD. Use of hydro-FDG PET in the detection of primary tumors of the stomach. J Nucl Med (Abstract). 2005;424P
|
10 |
Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasue N, et al. Long-term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach. J Am Coll Surg 1995;181:389-96
|
11 |
Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513-20
DOI
|
12 |
Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42
DOI
ScienceOn
|
13 |
Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on -FDG PET. J Nucl Med 2005;46:953-7
|
14 |
Yun M, Kim HK, Kim HR, Kim TS, Cho A, Lee JD. Histopathologic features of adenocarcinomas of the stomach affecting FDG uptake on PET. J Nucl Med (Abstract). 2006; 466P
|
15 |
Lim J, Yun M, Kim M, Hyung WJ, Park MS, Choi JY, et al. The role of CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143-56
DOI
ScienceOn
|
16 |
Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-56
DOI
ScienceOn
|
17 |
Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10
|
18 |
De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-9
DOI
ScienceOn
|
19 |
Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med 2005;30:118-9
DOI
ScienceOn
|
20 |
Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-55
DOI
ScienceOn
|
21 |
Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of -FDG PET. J Nucl Med 2003;44:1407-12
|
22 |
Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. Eur J Gynaecol Oncol 1998;19:434-7
|
23 |
Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14 Suppl 2:ii31-6
|
24 |
Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 2002;184: 433-6
DOI
ScienceOn
|
25 |
Tian J, Chen L, Wei B, Shao M, Ding Y, Yin D, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun 2004;25:825-31
DOI
ScienceOn
|
26 |
Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004;31:1471-78
DOI
|
27 |
Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-90
DOI
ScienceOn
|